Results 71 to 80 of about 2,530 (165)

Intravitreal Therapy for Diabetic Macular Edema: An Update [PDF]

, 2021
Diabetic macular edema (DME) represents a prevalent and disabling eye condition. Despite that DME represents a sight-Threatening condition, it is also among the most accessible to treatment.
Alessio G., Boscia F., Furino C., Reibaldi M.   +3 more
core   +1 more source

Indication‐Specific Dosing and Dose‐Evaluation Strategies in New Indications for Non‐Oncology Monoclonal Antibodies

The Journal of Clinical Pharmacology, Volume 65, Issue 7, Page 895-908, July 2025.
Abstract Compared to traditional small molecule drugs, monoclonal antibodies (mAbs) often display more complex pharmacokinetic (PK) and pharmacodynamic (PD) properties that may be impacted by disease‐specific factors. For mAbs in non‐oncology indications, where the same drug might be used for conditions involving different organ systems and/or having ...
Sherouk M. Tawfik, Fei Tang
wiley   +1 more source

Experience with Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration

Oftalʹmologiâ, 2023
Purpose: To assess efficacy and safety profile of intravitreal brolucizumab in patients with neovascular age-related macular degeneration (nAMD) in real clinical practice.Patients and Methods.
M. V. Budzinskaya, A. A. Plyukhova, Yu. S. Andreeva, A. G. Kurguzova, K. A. Budzinskaya   +4 more
doaj   +1 more source

Linking preclinical models to clinical realities: VEGF/VEGFR inhibitors and thrombotic microangiopathy in cancer therapy

iMetaOmics, Volume 2, Issue 2, June 2025.
This study investigates the risk of thrombotic microangiopathy (TMA) induced by vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) inhibitors in cancer therapy. Using data from the FDA Adverse Event Reporting System (FAERS), the WHO Global Database for Adverse Drug Reactions (Vigibase), and The Cancer ...
Aimin Jiang, Zhanzhi Li, Ying Liu, Junyi Shen, Quan Cheng, Anqi Lin, Peng Luo, Linhui Wang   +7 more
wiley   +1 more source

Escherichia coli in the production of biopharmaceuticals

Biotechnology and Applied Biochemistry, Volume 72, Issue 2, Page 528-541, April 2025.
Abstract Escherichia coli has shouldered a massive workload with the discovery of recombinant DNA technology. A new era began in the biopharmaceutical industry with the production of insulin, the first recombinant protein, in E. coli and its use in treating diabetes. After insulin, many biopharmaceuticals produced from E. coli have been approved by the
İbrahim İncir, Özlem Kaplan
wiley   +1 more source

Comparison of OCT Angiography Parameters after Administration of Intravitreal Brolucizumab versus Ranibizumab in Exudative Age-related Macular Degeneration

TNOA Journal of Ophthalmic Science and Research
Purpose: To compare the OCT angiography (OCTA)–derived parametric changes before and after intravitreal administration of ranibizumab and brolucizumab in patients with neovascular age-related macular degeneration (ARMD) and to compare the changes between
Sanjitha Vilma Moses, Aadithreya Varman, Dinesh Balakumar, Arulmozhi Varman   +3 more
doaj   +1 more source

Association of metabolomic aging acceleration and body mass index phenotypes with mortality and obesity‐related morbidities

Aging Cell, Volume 24, Issue 4, April 2025.
Metabolomic aging acceleration may help stratify mortality and obesity‐related morbidities risk across different BMI categories. Weight management should address Individuals with overweight or obesity, regardless of metabolomic aging, while delaying metabolomic aging is crucial for all metabolomically older groups, including those with normal weight ...
Xiaomin Zeng, Ruiye Chen, Danli Shi, Xiayin Zhang, Ting Su, Yaxin Wang, Yijun Hu, Mingguang He, Honghua Yu, Xianwen Shang   +9 more
wiley   +1 more source

Gains in the current understanding of managing neovascular AMD with brolucizumab

Journal of Ophthalmic Inflammation and Infection, 2023
Background Unresolved retinal fluid and high injection burden are major challenges for patients with neovascular age-related macular degeneration. Brolucizumab addresses these challenges by providing robust vision gains and superior fluid resolution ...
Bahram Bodaghi, Arshad M. Khanani, Ramin Khoramnia, Carlos Pavesio, Quan Dong Nguyen   +4 more
doaj   +1 more source

Peptide‐Bound Aflibercept Eye Drops for Treatment of Neovascular Age‐Related Macular Degeneration in Nonhuman Primates

Advanced Science, Volume 12, Issue 11, March 20, 2025.
This article demonstrates that the peptide bxyPenetratin (bxyWP) non‐covalently binds to the anti‐vascular endothelial growth factor (VEGF) protein aflibercept via hydrophobic interactions, enabling noninvasive delivery of aflibercept to the choroid and retina through conjunctival‐scleral pathway and effective inhibition of choroidal neovascularization
Xingyan Fan, Kuan Jiang, Yongqian Zhao, Benjamin TK Lee, Feiyang Geng, Marten E Brelen, Weiyue Lu, Gang Wei   +7 more
wiley   +1 more source

Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations

American Journal of Ophthalmology Case Reports, 2020
Purpose: To describe a case of unilateral retinal arteriolar occlusion following multiple intravitreal brolucizumab injections for neovascular age-related macular degeneration (nAMD).
Atul Jain, Sophaktra Chea, Wataru Matsumiya, M. Sohail Halim, Çigdem Yaşar, Guoping Kuang, Yasir J. Sepah, Arshad M. Khanani, Diana V. Do, Quan Dong Nguyen   +9 more
doaj   +1 more source